molecules of the month


reversible KRASG12D inhibitor

preclinical efficacy in cancer model

from SBDD around KRASG12C inhibitor

Journal of Medicinal Chemistry

Mirati Therapeutics, San Diego, CA

Chemical structure of molecule MRTX1133
2 mins read

MRTX1133 was nominated as December 2021’s cover molecule by reviewers Joachim Rudolph and Julien Lefranc. MRTX1133 is a non-covalent inhibitor of KRASG12D that demonstrated tumor regression in a mouse xenograft model when dosed IP (maximum efficacy at 10-30 mg/kg, activity as low as 3 mg/kg). Joachim says, “The discovery of MRTX1133 deserves major credit as the first reported potent and selective non-covalent mutant-specific KRAS inhibitor especially as the targeted G12D mutant is the most prevalent KRAS mutant (33% among KRAS mutant tumors). The paper represents a successful continuation of the work on KRAS G12C inhibitors demonstrating suitability of the same binding site (switch II pocket) for mutants outside of G12C.” “This reflects, in retrospect, the power of covalent screening as…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: